Alzamend Neuro (ALZN) news
Recent news
Alzamend Neuro Inc. files to withdraw registration statement
Alzamend Neuro Inc. has filed to withdraw its registration statement, according to recent regulatory filings. The move indicates the company is no longer pursuing an initial public offering (IPO) at this time. While the decision does not necessarily reflect financial distress, it may signal a…
AInvest Wire · 3d agoAlzamend Neuro regains compliance with Nasdaq listing standards
AInvest Wire · Sep 16, 2026Alzamend Neuro - files to register resale of up to 98.4 mln common shares by selling stockholder - SEC filing
AInvest Wire · Aug 21, 2026ImportantAlzamend Neuro shares rise 450% on partnership for PTSD treatment mid-stage study
Alzamend Neuro shares rise 450% on partnership for PTSD treatment mid-stage study Introduction: Alzamend Neuro (NASDAQ: ALZN), a clinical-stage biopharmaceutical company specializing in the development of treatments for Alzheimer's disease, Bipolar disorder, Major Depressive Disorder (MDD), and…
AInvest Wire · Aug 19, 2024Alzamend Neuro receives FDA ‘study may proceed’ notification for a Phase IIa clinical trial of Al001
AInvest Wire · Dec 11, 2023Light Horse does not author, endorse or verify the headlines, and their appearance here is not an endorsement of any view they express.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.